Keep your eyes on these two stocks in the months to come.
News & Analysis: Trillium Therapeutics
These stocks have soared while the overall market tanked. But are they buys?
Gilead Sciences and Forty Seven are reportedly tying the knot through a $4.9 billion buyout agreement. Shares of Trillium Therapeutics, a fellow CD47 drugmaker, are also jumping on this news.
Gilead is reportedly courting the cancer specialist Forty Seven about a possible buyout.